Susceptibilities of Mycobacterium malmoense determined at the growth optimum pH (pH 6.0)

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 5, 1998, Pages 430-434

  Heginbothom, M L ^a   Lindholm Levy, P J ^c   Heifets, L B ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c NONE

Author keywords

Antimicrobial susceptibility; Mycobacterium malmoense; PH

Indexed keywords

AMIKACIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CULTURE MEDIUM; DIAGNOSTIC VALUE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM MALMOENSE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RADIOMETRY;

ANTI-BACTERIAL AGENTS; CULTURE MEDIA; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM;

EID: 0031813554     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Marks J, Jenkins P A, Schaefer W B. Thin layer chromatography of mycobacterial lipids: an aid to classification. Tubercle 1971; 52: 219-224.
2. Schröder K H and Juhlin I. Mycobacterium malmoense sp. nov. Int J Syst Bacteriol 1977; 27: 241-246.
3. Jenkins P A. Mycobacterium malmoense. Tubercle 1985; 66: 93-196.
4. Schaubschlager W W, Schröder K H, Brockhausen G, et al. Atypical mycobacterial infections - diseases caused by Mycobacterium malmoense. Pneumologie 1990; 44: 699-703.
5. Bollert F G E, Watt B, Greening A P, et al. Non-tuberculous pulmonary infections in Scotland: a cluster in Lothian? Thorax 1995; 50: 188-190.
6. Katalia M L, Iivanaincn E, Torkko P, et al. Isolation of potentially pathogenic mycobacteria in the Finnish environment. Scand J Infect Dis 1996; Suppl 98: 9-11.
7. Tortoli E, Piersimoni C, Bartoloni A, et al. Mycobacterium malmoense in Italy: the modern Norman invasion? Eur J Epidemiol 1997; 13: 341-346.
8. Banks J, Jenkins P A, Smith A P. Pulmonary infection with Mycobacterium malmoense -a review of treatment and response. Tubercle 1985; 66: 197-203.
9. France A J, McLeod D T, Calder M A, Seaton A. Mycobacterium malmoense infections in Scotland: an increasing problem. Thorax 1987; 42: 593-595.
10. Marks J. The design of sensitivity tests on tubercle bacilli. Tubercle 1961; 42: 314-316.
11. Leat J L, Marks J. Improvement of drug-sensitivity tests on tubercle bacilli. Tubercle 1970; 51: 68-72.
12. Hunter A M, Campbell I A, Jenkins P A, Smith A P. Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. Thorax 1981; 36: 326-329.
13. Katalia M L, Mattila J, Brander E. Enhancement of growth of Mycobacterium malmoense by acidic pH and pyruvate. Eur J Clin Infect Dis 1989; 8: 998-1000.
14. Rastogi N, Khye S G. Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. Antimicrob Agents Chemother 1992; 36: 2841-2842.
15. Rastogi N, Khye S G, Bryskier A. Activities of roxithromycin alone and in combination with ethambutol, rifampicin, amikacin, ofloxacin and clofazimine against Mycobacterium avium complex. Antimicrob Agents Chemother 1994; 36: 1433-1438.
16. Telles M A S, Yates M D. Single and double drug susceptibility testing of Mycobacterium avium complex and mycobacteria other than tubercle (MOTT) by a micro-dilution broth minimum inhibitory concentration (MIC) method. Tubercle Lung Dis 1994; 75: 286-290.
17. Heifets L B. MIC as a quantitative measurement of susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother 1988; 32: 1131-1136.
18. Siddiqi S H, Heifets L B, Cynamon M H, et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol 1993; 31: 2332-2338.
19. Campbell I A, Jenkins P A. Opportunist mycobacterial infections. In: Brewis R A L, Corrin B, Geddes D M, Gibson G J eds. Respiratory Medicine. London: WB Saunders and Co Ltd; 1995, pp 840-847.
20. Sturgill-Koszycki S, Schlesinger P H, Chakraborty P, et al Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994; 263: 678-681.
21. Hoffner S, Henriques B, Petrini B, Kallenius C, Mycobacterium malmoense: an easily missed pathogen. J Clin Microbiol 1991; 29: 2673-2674.
22. Chapman J S, Bernard J S. The tolerance of unclassified mycobacteria. I. Limits of pH tolerance. Am J Respir Dis 1962; 86: 582-583.
23. Yajko D M, Nassos P S, Hadley K. Therapeutic implications of inhibition versus killing of M. avium complex by antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 117-120.
24. Barry V C, Buggle K, Byrne J, Conalty M L, Winder F. Absorption, distribution and retention of rimino-compounds in experimental animals. Irish J Med Sci 1960; 416: 345-352.
25. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampicin against M. avium complex. Antimicrob Agents Chemother 1991; 35: 462-470.
26. Duzgunes N, Permumal V K, Kesavalu L, Goldstein J A, Debs R J, Gangadharam P R J. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare infection in beige mice. Antimicrob Agents Chemother 1988; 32: 1404-1411.
27. Heifets L B. Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets L B ed. Drug susceptibility in the chemotherapy of mycobacterial infection. Florida: CRC Press, Inc. 1991; p 27.
28. Easmon C S F, Crane J P, Blowers A. Effect of ciprofloxacin on intracellular organisms: in vitro and in vivo studies. J Antimicrob Chemother 1986; 18(Suppl D): 43-48.
29. Heifets L B, Lindholm-Levy P J. Bacteriostatic and bactericidal activities of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 1987; 68: 267-276.
30. Fernandes P B, Hardy D J, McDaniel D, Hanson C W, Swanson R N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-1534.
31. Winder F G. Mode of action of antimycobacterial agents and associated aspects of molecular biology of the mycobacteria. In: Ratledge C and Stanford J L eds. The biology of the mycobacteria. London: Academic Press, 1989; p 405.
32. Lindholm-Levy P J, Heifets L B. Clofazimine and other rimino- compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex. Tubercle 1988; 69: 179-186.
33. Gangadharam P R J, Candler E R. Activity of some antileprosy compounds against Mycobacterium intracellulare m vitro. Am Rev Respir Dis 1977; 115: 705-707.
34. Kanther R. Myambutol: chemistry, pharmacology and toxicology. Antibiotica et Chemotherapia 1970; 16: 203-214.
35. Zimmer B L, DeYoung D R, Roberts G D. In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampicin and streptomycin against Mycobacterium avium-intracellulare complex. Antimicrob Agents Chemother 1982; 22: 148-150.
36. Hand L W, King-Tompson N L, Steinberg T H. Interactions of antibiotics and phagocytes. J Antimicrob Chemother 1983; 12 (Suppl.): 1.
37. Holdiness M R. Clinical pharmacokinetics of antituberculosis drugs. Clin Pharmacokinet 1984; 9: 511-544.
38. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 40: 1759-1767.